Ensysce Biosciences, Inc.
NASDAQ: ENSC0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- D. Lynn Kirkpatrick
- Employees
- 7
- Headquarters
- La Jolla, United States
- IPO year
- 2018
- Market cap
- $2.6M
- Website
- https://www.ensysce.com
Loading ENSC…
Loading profile data…Frequently asked questions about ENSC
What does Ensysce Biosciences, Inc. (ENSC) do?
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protec...
Where does ENSC trade?
Ensysce Biosciences, Inc. (ENSC) trades on the NASDAQ Capital Market.
What sector is ENSC in?
Ensysce Biosciences, Inc. (ENSC) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Ensysce Biosciences, Inc.?
D. Lynn Kirkpatrick is the chief executive officer of Ensysce Biosciences, Inc. (ENSC).
Where is Ensysce Biosciences, Inc. headquartered?
Ensysce Biosciences, Inc. is headquartered in United States.
Does ENSC pay a dividend?
Ensysce Biosciences, Inc. (ENSC) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ENSC go public?
Ensysce Biosciences, Inc. (ENSC) completed its initial public offering in 2018.